Skip to main content
Erschienen in: European Radiology 8/2009

01.08.2009 | Neuro

MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study

verfasst von: J. Bellmann-Strobl, H. Stiepani, J. Wuerfel, G. Bohner, F. Paul, C. Warmuth, O. Aktas, K. P. Wandinger, F. Zipp, R. Klingebiel

Erschienen in: European Radiology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to correlate magnetic resonance imaging (MRI)-based lesion load assessment with clinical disability in early relapsing remitting multiple sclerosis (RRMS). Seventeen untreated patients (ten women, seven men; mean age 33.0 ± 7.9 years) with the initial diagnosis of RRMS were included for cross-sectional as well as longitudinal (24 months) clinical and MRI-based assessment in comparison with age-matched healthy controls. Conventional MR sequences, MR spectroscopy (MRS) and magnetisation transfer imaging (MTI) were performed at 1.5 T. Lesion number and volume, MRS and MTI measurements for lesions and normal appearing white matter (NAWM) were correlated to clinical scores [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC)] for monitoring disease course after treatment initiation (interferon β-1a). MTI and MRS detected changes [magnetisation transfer ratio (MTR), N-acetylaspartate (NAA)/creatine ratio] in NAWM over time. EDSS and lesional MTR increases correlated throughout the disease course. Average MTR of NAWM raised during the study (p < 0.05) and correlated to the MSFC score (r = 0.476, p < 0.001). At study termination, NAA/creatine ratio of NAWM correlated to the MSFC score (p < 0.05). MTI and MRS were useful for initial disease assessment in NAWM. MTI and MRS correlated with clinical scores, indicating potential for monitoring the disease course and gaining new insights into treatment-related effects.
Literatur
1.
Zurück zum Zitat Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191PubMedCrossRef Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191PubMedCrossRef
2.
Zurück zum Zitat Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria". Ann Neurol 58(6):840–846PubMedCrossRef Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria". Ann Neurol 58(6):840–846PubMedCrossRef
3.
Zurück zum Zitat Filippi M, Rovaris M (2000) Magnetisation transfer imaging in multiple sclerosis. J Neurovirol 6(Suppl 2):S115–S1120PubMed Filippi M, Rovaris M (2000) Magnetisation transfer imaging in multiple sclerosis. J Neurovirol 6(Suppl 2):S115–S1120PubMed
4.
Zurück zum Zitat Tedeschi G, Bonavita S, McFarland HF et al (2002) Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44(1):37–42PubMedCrossRef Tedeschi G, Bonavita S, McFarland HF et al (2002) Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44(1):37–42PubMedCrossRef
5.
Zurück zum Zitat Inglese M, Rovaris M, Bianchi S et al (2001) Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber’s hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 70(4):444–449PubMedCrossRef Inglese M, Rovaris M, Bianchi S et al (2001) Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber’s hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 70(4):444–449PubMedCrossRef
6.
Zurück zum Zitat Narayana PA (2005) Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15(4 Suppl):46S–57SPubMedCrossRef Narayana PA (2005) Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15(4 Suppl):46S–57SPubMedCrossRef
7.
Zurück zum Zitat Horsfield MA (2005) Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15(4 Suppl):58S–67SPubMedCrossRef Horsfield MA (2005) Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15(4 Suppl):58S–67SPubMedCrossRef
8.
Zurück zum Zitat Pascual-Lozano A, Martinez-Bisbal M, Bosca I et al (2006) Axonal damage and inflammation in early multiple sclerosis: effects of subcutaneously interferon-beta-1a treatment. Mult Scler 12:S186 Pascual-Lozano A, Martinez-Bisbal M, Bosca I et al (2006) Axonal damage and inflammation in early multiple sclerosis: effects of subcutaneously interferon-beta-1a treatment. Mult Scler 12:S186
9.
Zurück zum Zitat Narayanan S, De Stefano N, Francis GS et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979–986PubMedCrossRef Narayanan S, De Stefano N, Francis GS et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979–986PubMedCrossRef
10.
Zurück zum Zitat Sarchielli P, Presciutti O, Tarducci R et al (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64(2):204–212PubMedCrossRef Sarchielli P, Presciutti O, Tarducci R et al (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64(2):204–212PubMedCrossRef
11.
Zurück zum Zitat Parry A, Corkill R, Blamire AM et al (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250(2):171–178PubMedCrossRef Parry A, Corkill R, Blamire AM et al (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250(2):171–178PubMedCrossRef
12.
Zurück zum Zitat Richert ND, Ostuni JL, Bash CN et al (1998) Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 19(9):1705–1713PubMed Richert ND, Ostuni JL, Bash CN et al (1998) Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 19(9):1705–1713PubMed
13.
Zurück zum Zitat Kita M, Goodkin DE, Bacchetti P et al (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54(9):1741–1745 Kita M, Goodkin DE, Bacchetti P et al (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54(9):1741–1745
14.
Zurück zum Zitat McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef
15.
Zurück zum Zitat Cutter GR, Baier ML, Rudick RA et al (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882PubMedCrossRef Cutter GR, Baier ML, Rudick RA et al (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882PubMedCrossRef
16.
Zurück zum Zitat Rovaris M, Filippi M, Minicucci L et al (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21(2):402–408PubMed Rovaris M, Filippi M, Minicucci L et al (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21(2):402–408PubMed
17.
Zurück zum Zitat Bakshi R, Thompson AJ, Rocca MA et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615–625PubMedCrossRef Bakshi R, Thompson AJ, Rocca MA et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615–625PubMedCrossRef
18.
Zurück zum Zitat Zivadinov R, Stosic M, Cox J et al (2008) The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 255(0):61–74PubMedCrossRef Zivadinov R, Stosic M, Cox J et al (2008) The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 255(0):61–74PubMedCrossRef
19.
Zurück zum Zitat Chen JT, Collins DL, Atkins HL et al (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63(2):254–262PubMedCrossRef Chen JT, Collins DL, Atkins HL et al (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63(2):254–262PubMedCrossRef
20.
Zurück zum Zitat Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45(1):37–45PubMedCrossRef Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45(1):37–45PubMedCrossRef
21.
Zurück zum Zitat Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68(22 Suppl 3):S72–S82PubMedCrossRef Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68(22 Suppl 3):S72–S82PubMedCrossRef
22.
Zurück zum Zitat Giacomini PS, Arnold DL (2008) Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 21(3):272–277PubMedCrossRef Giacomini PS, Arnold DL (2008) Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 21(3):272–277PubMedCrossRef
23.
Zurück zum Zitat Rovira A, Leon A (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol 67(3):409–414PubMedCrossRef Rovira A, Leon A (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol 67(3):409–414PubMedCrossRef
24.
Zurück zum Zitat Inglese M (2006) Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol 27(5):954–957PubMed Inglese M (2006) Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol 27(5):954–957PubMed
25.
Zurück zum Zitat Khaleeli Z, Sastre-Garriga J, Ciccarelli O et al (2007) Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78(10):1076–1082PubMedCrossRef Khaleeli Z, Sastre-Garriga J, Ciccarelli O et al (2007) Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78(10):1076–1082PubMedCrossRef
26.
Zurück zum Zitat Wattjes MP, Harzheim M, Lutterbey GG et al (2008) Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 50(2):123–129PubMedCrossRef Wattjes MP, Harzheim M, Lutterbey GG et al (2008) Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 50(2):123–129PubMedCrossRef
27.
Zurück zum Zitat De Stefano N, Guidi L, Stromillo ML et al (2003) Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 24(Suppl 5):S283–S286PubMedCrossRef De Stefano N, Guidi L, Stromillo ML et al (2003) Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 24(Suppl 5):S283–S286PubMedCrossRef
28.
Zurück zum Zitat Filippi M, Rocca MA, Comi G (2003) The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2(6):337–346PubMedCrossRef Filippi M, Rocca MA, Comi G (2003) The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2(6):337–346PubMedCrossRef
29.
Zurück zum Zitat Pascual AM, Martinez-Bisbal MC, Bosca I et al (2007) Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology 69(1):63–67PubMedCrossRef Pascual AM, Martinez-Bisbal MC, Bosca I et al (2007) Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology 69(1):63–67PubMedCrossRef
30.
Zurück zum Zitat Inglese M, Li BS, Rusinek H et al (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50(1):190–195PubMedCrossRef Inglese M, Li BS, Rusinek H et al (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50(1):190–195PubMedCrossRef
31.
Zurück zum Zitat Wattjes MP, Harzheim M, Lutterbey GG et al (2008) High field MR imaging and (1)H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 255(1):56–63PubMedCrossRef Wattjes MP, Harzheim M, Lutterbey GG et al (2008) High field MR imaging and (1)H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 255(1):56–63PubMedCrossRef
32.
Zurück zum Zitat Rieckmann P (2005) Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 12(2):42–51PubMed Rieckmann P (2005) Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 12(2):42–51PubMed
33.
Zurück zum Zitat Neema M, Stankiewicz J, Arora A et al (2007) MRI in multiple sclerosis: what’s inside the toolbox? Neurotherapeutics 4(4):602–617PubMedCrossRef Neema M, Stankiewicz J, Arora A et al (2007) MRI in multiple sclerosis: what’s inside the toolbox? Neurotherapeutics 4(4):602–617PubMedCrossRef
34.
Zurück zum Zitat Adalsteinsson E, Langer-Gould A, Homer RJ et al (2003) Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24(10):1941–1945PubMed Adalsteinsson E, Langer-Gould A, Homer RJ et al (2003) Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24(10):1941–1945PubMed
35.
Zurück zum Zitat Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294PubMedCrossRef Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294PubMedCrossRef
36.
Zurück zum Zitat PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet Neurol 352(9139):1498–1504 PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet Neurol 352(9139):1498–1504
37.
Zurück zum Zitat Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397PubMedCrossRef Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397PubMedCrossRef
38.
Zurück zum Zitat Chen JT, Kuhlmann T, Jansen GH et al (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36(4):1152–1158PubMedCrossRef Chen JT, Kuhlmann T, Jansen GH et al (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36(4):1152–1158PubMedCrossRef
39.
Zurück zum Zitat Deloire MS, Salort E, Bonnet M et al (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(4):519–526PubMedCrossRef Deloire MS, Salort E, Bonnet M et al (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(4):519–526PubMedCrossRef
40.
Zurück zum Zitat Vrenken H, Pouwels PJ, Ropele S et al (2007) Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 13(6):708–716PubMedCrossRef Vrenken H, Pouwels PJ, Ropele S et al (2007) Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 13(6):708–716PubMedCrossRef
41.
Zurück zum Zitat Laule C, Vavasour IM, Whittall KP et al (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250(8):924–931PubMedCrossRef Laule C, Vavasour IM, Whittall KP et al (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250(8):924–931PubMedCrossRef
42.
Zurück zum Zitat Horakova D, Cox JL, Havrdova E et al (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 79(4):407–414PubMedCrossRef Horakova D, Cox JL, Havrdova E et al (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 79(4):407–414PubMedCrossRef
43.
Zurück zum Zitat Davies GR, Ramio-Torrenta L, Hadjiprocopis A (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 75(7):998–1002PubMedCrossRef Davies GR, Ramio-Torrenta L, Hadjiprocopis A (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 75(7):998–1002PubMedCrossRef
44.
Zurück zum Zitat Oreja-Guevara C, Charil A, Caputo D et al (2006) Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63(5):736–440PubMedCrossRef Oreja-Guevara C, Charil A, Caputo D et al (2006) Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63(5):736–440PubMedCrossRef
Metadaten
Titel
MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study
verfasst von
J. Bellmann-Strobl
H. Stiepani
J. Wuerfel
G. Bohner
F. Paul
C. Warmuth
O. Aktas
K. P. Wandinger
F. Zipp
R. Klingebiel
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 8/2009
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-009-1364-z

Weitere Artikel der Ausgabe 8/2009

European Radiology 8/2009 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.